e-Therapeutics Ltd., Khandelwal Laboratories deal

Khandelwal received exclusive rights to develop and market in India e-Therapeutics' ETX9101 for asthma, ETS6103 for severe major depressive disorder and ETX1153b for methicillin-resistant Staphylococ...